BCLI

SEC source: 0001104659-20-044270 · tm2014134d4_4.xml · derivative · entry 1

FRENKEL JACOB A · CIK 0001237418 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-04-06

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on the one month anniversary of the date of grant until fully vested and exercisable on the 12 month anniversary of the date of grant, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date.

SEC source: 0001104659-20-044267 · tm2014134d2_form4.xml · nonDerivative · entry 1

Abbhi Sankesh · CIK 0001806887 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,657

F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on the one month anniversary of the date of grant until fully vested on the 12 month anniversary of the date of grant, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date.

SEC source: 0001104659-20-033203 · tm2012148d1_4.xml · derivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2030-03-09

F1 · derivative.exercise_date: Option becomes vested and exercisable as to 25% of the number of shares on each of the first four anniversaries of the grant date until fully vested and exercisable on the fourth anniversary of the grant date.

SEC source: 0001104659-20-030195 · tm2011847d1_form4.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,540

F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-20-021983 · tm205737d3_4.xml · nonDerivative · entry 2

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,862

F2 · shares: Shares acquired are shares of restricted stock awarded on February 1, 2020 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-19-076291 · tm1927404-3_4.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,655

SEC source: 0001104659-19-076290 · tm1927404-2_4.xml · nonDerivative · entry 1

Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,600

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.89 to $3.9789, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-19-076289 · tm1927404-1_4.xml · nonDerivative · entry 1

Araya Arturo · CIK 0001699800 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,608

SEC source: 0001104659-20-021983 · tm205737d3_4.xml · nonDerivative · entry 1

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,791

F1 · shares: Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-20-021982 · tm205737d2_4.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

F1 · shares: Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-20-021985 · tm205737d5_4.xml · derivative · entry 1

Yablonka Uri · CIK 0001608814 · Director · EVP and Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,333

Underlying: Common Stock · 13,333 shares

Expires 2029-12-12

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested and exercisable on December 12, 2020, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-20-021984 · tm205737d4_4.xml · derivative · entry 1

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,333

Underlying: Common Stock · 25,333 shares

Expires 2029-12-12

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested and exercisable on December 12, 2020, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-20-021981 · tm205737d1_4.xml · nonDerivative · entry 1

TAUB MALCOLM S · CIK 0001305117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,332

F1 · shares: Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-19-043864 · tv529006_4.xml · derivative · entry 3

Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-09-05

F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on the first anniversary of the date of grant, and the remaining shares underlying the option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.

SEC source: 0001144204-19-043864 · tv529006_4.xml · derivative · entry 2

Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-09-05

F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on the first anniversary of the date of grant, and the remaining shares underlying the option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.

SEC source: 0001144204-19-043864 · tv529006_4.xml · nonDerivative · entry 1

Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: Shares acquired are shares of restricted stock awarded on September 6, 2019 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on September 6, 2020, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date.

SEC source: 0001144204-19-043047 · tv528639_4.xml · derivative · entry 5

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,666 shares

Expires 2019-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested and became exercisable as to 33.3% of the number of shares subject to the option on each of August 31, 2010, August 31, 2011 and August 31, 2012.

SEC source: 0001144204-19-043047 · tv528639_4.xml · derivative · entry 4

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,666 shares

Expires 2019-12-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-19-043047 · tv528639_4.xml · nonDerivative · entry 3

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,833

F1 · price: This is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001144204-19-043047 · tv528639_4.xml · nonDerivative · entry 2

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-19-043047 · tv528639_4.xml · nonDerivative · entry 1

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,499

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-19-036266 · tv525662_4.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,166,155

F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2019 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

F2 · balance_after: Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 138,806 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.

SEC source: 0001144204-19-013081 · tv514173_form4.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,655

F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2019 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001144204-19-009627 · tv514175_form4.xml · nonDerivative · entry 1

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,791

F1 · shares: Shares acquired are shares of restricted stock awarded on February 1, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2019 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-19-000986 · tv509629_4.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Meadowlark Management LLC

Disclosed balance after: 7,175

F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.

SEC source: 0001144204-18-062654 · tv507905_4.xml · nonDerivative · entry 2

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,290

SEC source: 0001144204-18-062654 · tv507905_4.xml · nonDerivative · entry 1

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,623

F1 · shares: Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-18-062657 · tv507907_4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,558

F1 · shares: Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-18-062653 · tv507903_4.xml · derivative · entry 1

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,333

Underlying: Common Stock · 25,333 shares

Expires 2028-11-30

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested and exercisable on November 30, 2019, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-18-062651 · tv507902_4.xml · derivative · entry 1

Yablonka Uri · CIK 0001608814 · Director · EVP and Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,333

Underlying: Common Stock · 13,333 shares

Expires 2028-11-30

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested and exercisable on November 30, 2019, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-18-062649 · tv507901_4.xml · nonDerivative · entry 1

TAUB MALCOLM S · CIK 0001305117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,332

F1 · shares: Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-18-066056 · tv509467_4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By The C. Schor Irrevocable Trust

Disclosed balance after: 121,558

F1 · shares: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001144204-18-066056 · tv509467_4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

F1 · shares: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F2 · balance_after: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018.

SEC source: 0001144204-18-047847 · tv501988_4.xml · derivative · entry 2

Araya Arturo · CIK 0001699800 · Director · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2028-08-27

F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.

SEC source: 0001144204-18-047847 · tv501988_4.xml · nonDerivative · entry 1

Araya Arturo · CIK 0001699800 · Director · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,608

F1 · shares: Represents unvested shares of restricted common stock awarded by Issuer to Reporting Person on February 26, 2018 and March 26, 2018, forfeited pursuant to Reporting Person's August 28, 2018 employment agreement with Issuer.

SEC source: 0001144204-18-040473 · tv498316_4.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,134,970

F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2018 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

F2 · balance_after: Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 138,806 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.

SEC source: 0001144204-18-016909 · tv489424_4.xml · nonDerivative · entry 1

Araya Arturo · CIK 0001699800 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,413

F1 · shares: Shares acquired are shares of restricted stock awarded on March 26, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan and the reporting person's election to the Governance, Nominating and Compensation Committee. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on April 26, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a member of the Governance, Nominating and Compensation Committee of the Board of Directors of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-18-015059 · tv488679_4.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Meadowlark Management LLC

Disclosed balance after: 5,700

F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.

SEC source: 0001144204-18-015580 · tv488647_4.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,885

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.59 to $3.60, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001144204-18-015760 · tv488977_4a.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Meadowlark Management LLC

Disclosed balance after: 5,700

F2 · kind: This Form 4/A is being filed to reflect that this was an open market purchase of the Issuer's securities (On March 16, 2018 this transaction was incorrectly reported on Form 4 as an acquisition pursuant to Rule 16b-3(d).

F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.

SEC source: 0001144204-18-015759 · tv488976_4a.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,885

F2 · kind: This Form 4/A is being filed to reflect that this transaction was an open market purchase of the Issuer's securities (on March 19, 2018 this transaction was incorrectly reported on Form 4 as an acquisition pursuant to Rule 16b-3(d)).

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.59 to $3.60, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001144204-18-016910 · tv489540_4.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,770

F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2018 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001144204-18-011819 · tv487354_4.xml · nonDerivative · entry 1

Araya Arturo · CIK 0001699800 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,164

F1 · shares: Shares acquired are shares of restricted stock awarded on February 26, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 26, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-18-005728 · tv484711_4.xml · nonDerivative · entry 1

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,623

F1 · shares: Shares acquired are shares of restricted stock awarded on February 1, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-17-060168 · tv478601_4.xml · derivative · entry 2

Rubin Eyal · CIK 0001721411 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,686

Underlying: Common Stock · 93,686 shares

Expires 2027-11-20

F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through each applicable vesting date.

SEC source: 0001144204-17-060168 · tv478601_4.xml · nonDerivative · entry 1

Rubin Eyal · CIK 0001721411 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: Shares acquired are shares of restricted stock awarded on November 20, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 100% of the award on April 1, 2018, provided that the Reporting Person remains continuously employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through the vesting date.

SEC source: 0001144204-17-058401 · tv479020_4.xml · derivative · entry 1

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,333

Underlying: Common Stock · 25,333 shares

Expires 2027-11-10

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested and exercisable on November 10, 2018, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-17-058402 · tv479021_4.xml · nonDerivative · entry 1

SHORR ROBERT G L · CIK 0001197981 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,731

F1 · shares: Shares acquired are shares of restricted stock awarded on November 10, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-17-058399 · tv479019_4.xml · derivative · entry 1

Yablonka Uri · CIK 0001608814 · Director · EVP and Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,333

Underlying: Common Stock · 13,333 shares

Expires 2027-11-10

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested and exercisable on November 10, 2018, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001144204-17-058398 · tv479018_4.xml · nonDerivative · entry 1

TAUB MALCOLM S · CIK 0001305117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,332

F1 · shares: Shares acquired are shares of restricted stock awarded on November 10, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.